Celltrion’s Remsima SC Biosimilar Starts Strong In EU5 Countries

New Study Follows Approval For IBD Indications Last Year

Celltrion is capitalizing on the earlier strength of its intravenous Remsima formulation to make waves with its innovative subcutaneous version, according to the results of a new study sampling nearly 250 gastroenterologists in EU5 countries.

IBD
The report sampled 246 EU5 gastroenterologists in November and December last year. • Source: Shutterstock

Less than a year after its introduction in Europe, Celltrion’s Remsima SC subcutaneous infliximab biosimilar has captured material market share among inflammatory bowel disease patients in the EU5 countries, including the UK, according to a newly-released report sampling nearly 250 EU5 gastroenterologists in November and December last year.

Aided by the cannibalization of the intravenous formulation of Remsima – a biosimilar to Janssen’s Remicade – and the decline...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.